Evidence map›Paper›PMID 41403871›Full record

ArticleAdvances in hematology2025

Hyper-CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study.

Brenner Sabando, Jairo Quinonez, Andrés Orquera, Danilo Navarrete, Jhoanna Ramírez, Lorena Sanchez, Teodoro Chisesi, Jorge Oliveros, María A Pacheco, María C Trujillo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Brenner SabandoDepartment of Hematology, IRHED Medical Specialties Center, Guayaquil, Ecuador.ORCID https://orcid.org/0000-0002-4462-5411
Jairo QuinonezDepartment of Hematology, IRHED Medical Specialties Center, Guayaquil, Ecuador.
Andrés OrqueraHematology Service, Carlos Andrade Marín Hospital, Quito, Ecuador.ORCID https://orcid.org/0000-0003-0143-2967
Danilo NavarreteHemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Manabi, Ecuador.ORCID https://orcid.org/0009-0009-2792-6456
Jhoanna RamírezHematology Service, Teodoro Maldonado Carbo Hospital, Guayaquil, Ecuador.ORCID https://orcid.org/0009-0006-7949-0496
Lorena SanchezDepartment of Hematology, Abel Gilbert Ponton Hospital, Guayaquil, Ecuador.
Teodoro ChisesiOncology Department, Angela Serra Association for Cancer Research, Lecce, Italy.
Jorge OliverosHematology Service, Luis Vernaza Hospital, Guayaquil, Ecuador.ORCID https://orcid.org/0000-0002-9262-7171
María A PachecoHemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Cuenca, Ecuador.ORCID https://orcid.org/0000-0001-7628-8619
María C TrujilloDepartment of Hematology, Eugenio Espejo Hospital, Quito, Ecuador, hee.gob.ec.
Carlos PlazaHemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Guayaquil, Ecuador.ORCID https://orcid.org/0009-0008-1279-8749
Yaira LoorHematology Service, Luis Vernaza Hospital, Guayaquil, Ecuador.ORCID https://orcid.org/0009-0009-8678-3790

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Hyper-CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission-leading treatment option for adults with acute lymphoblastic leukemia (ALL). Objective: To determine the outcomes of adults with ALL treated with the Hyper-CVAD protocol in Ecuador. Methods: This multicenter, retrospective, cross-sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper-CVAD protocol in 8 specialized centers. Results: 139 patients with ALL treated with the Hyper-CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B-type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49-14.50) with a 5-year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase. Conclusion: Adult patients treated with the Hyper-CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment-related toxicity.

Identifiers

PMID41403871
PMCPMC12703404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.